- Home
- LNTH
as 07-26-2024 4:00pm EST
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.
Upcoming Earnings Alert:
Get ready for potential market movements as Lantheus Holdings Inc. LNTH prepares to release earnings report on 31 Jul 2024.
| Founded: | 1956 | Country: | United States |
| Employees: | N/A | City: | NORTH BILLERICA |
| Market Cap: | 5.4B | IPO Year: | 2015 |
| Target Price: | $114.50 | AVG Volume (30 days): | 1.5M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 6.55 | EPS Growth: | N/A |
| 52 Week Low/High: | $50.20 - $126.89 | Next Earning Date: | 07-31-2024 |
| Revenue: | $1,365,620,000 | Revenue Growth: | 32.98% |
| Revenue Growth (this year): | 19.17% | Revenue Growth (next year): | 3.37% |
Stock Insider Trading Activity of Lantheus Holdings Inc. (LNTH)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sabens Andrea | LNTH | Chief Accounting Officer | Jul 15 '24 | Sell | $124.96 | 1,796 | $224,422.77 | 60,420 | SEC Form 4 |
| Sabens Andrea | LNTH | Chief Accounting Officer | Jul 15 '24 | Sell | $123.15 | 341 | $41,994.15 | 62,216 | SEC Form 4 |
| Sabens Andrea | LNTH | Chief Accounting Officer | Jun 13 '24 | Sell | $79.77 | 341 | $27,201.57 | 62,557 | SEC Form 4 |
| Blanchfield Paul | LNTH | President | May 31 '24 | Sell | $80.82 | 1,179 | $95,286.78 | 101,498 | SEC Form 4 |
| Niedzwiecki Daniel | LNTH | See Remarks | May 30 '24 | Sell | $79.86 | 12,873 | $1,028,037.78 | 80,244 | SEC Form 4 |
| Maeusli Heinz Christoph | LNTH | Director | May 28 '24 | Sell | $78.95 | 12,307 | $971,637.65 | 29,399 | SEC Form 4 |
| Maeusli Heinz Christoph | LNTH | Director | May 28 '24 | Sell | $79.67 | 5,959 | $474,753.53 | 23,440 | SEC Form 4 |
| Maeusli Heinz Christoph | LNTH | Director | May 28 '24 | Sell | $80.29 | 100 | $8,029.00 | 23,340 | SEC Form 4 |
| McHugh Julie | LNTH | Director | May 28 '24 | Sell | $78.50 | 2,500 | $196,250.00 | 28,617 | SEC Form 4 |
| Sabens Andrea | LNTH | Chief Accounting Officer | May 13 '24 | Sell | $76.89 | 341 | $26,219.49 | 62,898 | SEC Form 4 |
| Sabens Andrea | LNTH | Chief Accounting Officer | Apr 15 '24 | Sell | $61.24 | 341 | $20,882.84 | 63,239 | SEC Form 4 |
| Marshall Robert J. Jr. | LNTH | CFO and Treasurer | Mar 15 '24 | Sell | $60.00 | 20,000 | $1,200,000.00 | 113,749 | SEC Form 4 |
| Sabens Andrea | LNTH | Chief Accounting Officer | Mar 13 '24 | Sell | $60.48 | 341 | $20,623.68 | 63,204 | SEC Form 4 |
| Blanchfield Paul | LNTH | President | Mar 7 '24 | Sell | $61.96 | 18,023 | $1,116,705.08 | 103,357 | SEC Form 4 |
| LENO SAM R | LNTH | Director | Mar 5 '24 | Sell | $64.47 | 1,729 | $111,468.63 | 58,253 | SEC Form 4 |
| LENO SAM R | LNTH | Director | Mar 5 '24 | Sell | $65.44 | 316 | $20,679.04 | 57,937 | SEC Form 4 |
| LENO SAM R | LNTH | Director | Mar 5 '24 | Sell | $62.12 | 529 | $32,861.48 | 59,453 | SEC Form 4 |
| LENO SAM R | LNTH | Director | Mar 5 '24 | Sell | $63.26 | 400 | $25,304.00 | 59,053 | SEC Form 4 |
| LENO SAM R | LNTH | Director | Mar 5 '24 | Sell | $64.24 | 1,116 | $71,691.84 | 57,937 | SEC Form 4 |
| LENO SAM R | LNTH | Director | Mar 4 '24 | Sell | $64.81 | 5,025 | $325,670.25 | 75,301 | SEC Form 4 |
| LENO SAM R | LNTH | Director | Mar 4 '24 | Sell | $65.60 | 17,364 | $1,139,078.40 | 57,937 | SEC Form 4 |
| Heino Mary Anne | LNTH | Director | Mar 4 '24 | Sell | $64.81 | 34,512 | $2,236,750.33 | 310,994 | SEC Form 4 |
| Heino Mary Anne | LNTH | Director | Mar 4 '24 | Sell | $65.59 | 59,251 | $3,886,516.02 | 251,743 | SEC Form 4 |
| Heino Mary Anne | LNTH | Director | Mar 4 '24 | Sell | $66.23 | 100 | $6,622.50 | 251,643 | SEC Form 4 |
| Sabens Andrea | LNTH | Chief Accounting Officer | Feb 13 '24 | Sell | $55.31 | 341 | $18,860.71 | 58,403 | SEC Form 4 |
Latest Lantheus Holdings Inc. News
LNTH Breaking Stock News: Dive into LNTH Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
B. Riley Adjusts Lantheus Holdings' PT to $146 From $105, Maintains Buy Rating
Argus Research
3 days ago
LNTH: Lowering target price to $121.00
Medical Device Network
4 days ago
Nanotechnology in medicine: Who are the leading public companies?
MT Newswires
7 days ago
JonesTrading Adjusts Price Target on Lantheus Holdings to $137 From $128, Maintains Buy Rating
MT Newswires
9 days ago
Lantheus Holdings Insider Sold Shares Worth $266,417, According to a Recent SEC Filing
GlobeNewswire
9 days ago
Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
Argus Research
10 days ago
LNTH: Raising target price to $124.00
MT Newswires
11 days ago
Lantheus Holdings Acquires Meilleur Technologies
Compare LNTH vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LNTH Lantheus Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.